SECreport
Form 4 CYTOKINETICS INC For: Jan 16 Filed by: McDowell Caryn Gordon

Last cytokinetics, inc earnings: 11/1 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
IMPACT SNAPSHOT | EVENT TIME: | CYTK | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CYTK alerts
CYTK alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Inc news events
Weekly update
A roundup of the hottest topics
CYTK
NEWS
NEWS
- Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure[GlobeNewswire]
- Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator[GlobeNewswire]
- Cytokinetics to Announce Fourth Quarter Results on February 21, 2019[GlobeNewswire]
- Cytokinetics up 4% premarket on FDA signoff on endpoint for pivotal study of reldesmetiv in SMA [Seeking Alpha][Seeking Alpha]
- Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA[GlobeNewswire]
- More
CYTK
SEC Filings
SEC Filings
- 2/21/19 - Form 8-K
- 2/20/19 - Form 8-K
- 2/14/19 - Form SC
- CYTK's page on the SEC website
- More